XNAS · Biotechnology
Last stored close · Nov 9, 2026
Close · Nov 9, 2026
$12.50+5.22%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
51/100
Moderate
Score components
TickerWhale View
AbCellera Biologics scores 51 out of 100 overall, which we rate moderate. Risk is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Valuation
- Risk
What to watch
- Quality & growth
Quality & growth
30%28Weak
- Revenue growth 101.3%
- EPS growth n/a
Valuation
25%51Moderate
- P/E -23.2
- EV/Sales 55.9
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#89 / 139sector rank by TickerWhale Score
TickerWhale Score 51 vs sector average 54.6 (-3.6)
Revenue growth (industry)Top 20%
Return on equity (industry)Top 48%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
68/100Positive vs universe
Ranks 68th of 100 covered names on our technical composite — the composite itself scores 68/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 1 sell · 4 neutral of 8 votes
TickerWhale rates ABCL's technical setup strong — 68th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+76.6%
- vs 50-day+1.6%
Momentum
Mixed
- RSI (14)52 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength11· weak trend
- MACD (12,26,9)sell(histogram -0.046)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 1 sell · 4 neutral.
Result — 3 buy vs 1 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-09 · revised_latestValuation multiples
- P/E (TTM)-23.2 · TTM loss
- P/S (TTM)57.7
- P/B4.3
- EV/EBITDA—
- EV/Sales55.9
- PEG—
Profitability & returns
- Gross margin—
- Net margin-248.8%
- ROE-18.0%
- Debt/Equity0.00
Growth
- Revenue growth (YoY)101.3%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $3.8B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABCLCurrentAbCellera Biologics | 51 | 68 | -23.2 | — | 4.3 | 55.9 | $12.50 | +5.22% | +101.3% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 82 | 102.1 | — | 12.6 | 9.7 | $98.76 | +5.22% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.8 | — | 5.2 | 1.6 | $289.00 | +2.00% | +7.5% | ||
| EXELExelixis | 77 | 89 | 21.6 | — | 10.1 | 7.5 | $71.74 | +3.12% | +9.2% | ||
| TGTXTG Therapeutics | 77 | 85 | 22.6 | — | 16.5 | 12.8 | $63.38 | +5.94% | +76.1% | ||
| OSCROscar Health Inc - | 74 | 66 | 19.5 | — | 5.2 | 0.5 | $32.14 | +4.86% | +43.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.